Physician profile
Marisa E Kaplan
NPI 1598230831
$3,865.80
in general payments reported to CMS, 2019-2025
19 companies · $627 in 2025
The $627 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,394 · 2022: $795 · 2023: $499 · 2024: $552 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,534.22 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Esperion Therapeutics, INC. | $427.47 | 2021-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $400.91 | 2021-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $398.18 | 2022-2025 | Camzyos |
| Abbott Laboratories | $320.04 | 2024-2025 | Optis, Thoratec Heartmate 3 Lvas Implant Kit, Coroflow |
| Janssen Pharmaceuticals, INC | $270.36 | 2021-2024 | Xarelto |
| Amgen INC. | $141.38 | 2022-2023 | Repatha |
| Tactile Systems Technology INC | $53.97 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Kestra Medical Technology Services, INC. | $46.49 | 2023 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $43.45 | 2025 | |
| Merck Sharp & Dohme LLC | $39.45 | 2022 | |
| Novartis Pharmaceuticals Corporation | $32.27 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $29.63 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.45 | 2025 | Jardiance |
| Recor Medical INC | $25.69 | 2025 | Paradise Ultrasound Renal Denervation System |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $20.65 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $20.05 | 2024 | Arcalyst |
| Celgene Corporation | $19.04 | 2021 | |
| Boston Scientific Corporation | $15.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marisa Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.